Tuesday, January 28, 2020 8:46:21 AM
Research member of Inspyr Therapeutics, Søren Brøgger Christensen.
Still investigating and publishing 1/27/2020 information on Thapsigargin and Prodrug Mipsagargin and its ability to Stabilize cancer patients.
https://biosignaling.biomedcentral.com/articles/10.1186/s12964-019-0499-z
"Moreover, one prodrug has reached the stage of clinical phase II trials, where it recently was demonstrated to promote prolonged disease stabilization in patients with advanced hepatocellular carcinoma [59]"
Recent RBSH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:19:43 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:36:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM